News Announcement

Zydus Lifesciences: Announcement under Regulation 30 (LODR)-Press Release / Media Release

Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS).


दूसरी कैटेगरी